AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03739502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant.
Study NCT01430533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid pre foam formulation
Study NCT01430533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle pre foam formulation
Study NCT01430533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT04277793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored self-guided problem solving
Description: Problem Solving is a behavioral modification intervention focusing on the training of adaptive problem-solving skills in order to cope more effectively with everyday stressful events.
Study NCT00295490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Devil Claw
Description: Dose ranging study so will elucidate dose Frequency is four times daily
Study NCT01975831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study NCT02039440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: One-time blood draw
Study NCT02925793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107
Study NCT02925793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Study NCT02885168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Activated Protein C
Description: 24 μg/kg/h during 96 hours - intravenous injection
Study NCT03680131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 2.0%
Description: EB01 Cream containing 2.0% EB01 w/w applied BID
Study NCT06212739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Diode laser used to effect closure of the anal fistula tract
Study NCT00295490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has same dosing freq as for active intervention and for same time period
Study NCT02754076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX 250
Description: Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Study NCT00949819 — intervention group
Intervention type: OTHER
Intervention: Active surveillance
Description: Serial, long term data collection and active surveillance
Study NCT06212739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIFT
Description: The intersphincteric portion of the fistula is excised and ligated.
Study NCT00894855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education about sun protection
Description: This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
Study NCT02727868 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: blood samples
Study NCT03978754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICG lymphography、CM、VD、Bioelectrical impedance technology、self-report
Description: All of these methods are used for patients visiting the lymphedema clinic to assess whether they have developed lymphedema.
Study NCT03978754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance technology、CM
Description: These two methods are routine evaluation methods for breast cancer patients before surgery
Study NCT02418299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IncontiLase Er:YAG laser treatment
Description: Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
Study NCT04507672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Description: Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
Study NCT04507672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluid resuscitation
Description: Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (125 mg)
Description: Clarithromycin DST (125.0 mg clarithromycin / straw).
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (187.5 mg)
Description: Clarithromycin DST (187.5 mg clarithromycin / straw).
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin DST (250 mg)
Description: Clarithromycin DST (250.0 mg clarithromycin / straw).
Study NCT04016051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin Syrup (125 mg)
Description: Clarithromycin Syrup 2.5 ml (125 mg).
Study NCT03195790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based pediatric obesity treatment
Description: Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
Study NCT03195790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based pediatric obesity treatment
Description: Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
Study NCT01927562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractyl Duodenal Remodeling System
Study NCT01631357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cell
Description: CIK cell injection
Study NCT01631357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: Gemcitabine injection
Study NCT01631357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Injection
Description: Gemcitabine injection
Study NCT01631357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Cisplatin injection
Study NCT01631357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin injection
Study NCT03085732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation with Saline Solution
Description: During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
Study NCT01120327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01120327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine
Study NCT00673673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
Study NCT00673673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
Study NCT02501356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ISOThrive Supplement
Description: Consumption of ISOThrive supplements for 3 months
Study NCT02501356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Boiled Rice
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+0.37 gr mulberry fruit powdered extract
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+0.75 gr mulberry fruit powdered extract
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+1.12 gr mulberry fruit powdered extract
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Rice+1.50 gr mulberry fruit powdered extract
Study NCT00894855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biometric feedback
Description: Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
Study NCT00894855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dermatologist skin exam
Description: Full body skin exam.
Study NCT03221049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: radiomics
Study NCT00750243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-NS001
Description: 1200 mg b.i.d. p.o. for 7.5 days
Study NCT00750243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Description: 500 mg b.i.d. p.o. for 7.5 days
Study NCT04184947 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
Study NCT04184947 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
Study NCT01954277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Eletroacupuncture performed using acupuncture needles.
Study NCT01954277 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Sham
Description: Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
Study NCT02795858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Study NCT02795858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin Analog
Study NCT01135784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MIGRA-ZEN RELIEF PLUS
Description: one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Porridge
Study NCT04256746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice porridge+1.50 gr mulberry fruit powdered extract
Study NCT04440917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, iv, on day 1, 15, 29, 43
Study NCT04440917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg po, qd, 28 days as a cycle, 2 cycles in total
Study NCT00758862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% TD1414 Cream
Description: Application 3 times daily for 7 days
Study NCT00751101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
Study NCT01135784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Migrazen relief plus
Description: 2 capsule dose per 24 hours for 90 days
Study NCT04341337 — intervention group
Intervention type: OTHER
Intervention: interview
Description: questionnaire about ethics in surgery
Study NCT00185757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Killer Cells
Description: CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
Study NCT01983735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TELMINUVO Tab. (80/2.5mg)
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks.
Study NCT01983735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TELMINUVO Tab. (80/5mg)
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks.
Study NCT01983735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg
Description: * S-amlodipine 2.5mg QD 2 weeks~* With the others investigation product placebo 1 tab QD 2 weeks.
Study NCT01983735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: * S-amlodipine 5mg QD 6weeks~* With the others investigation product placebo 1 tab QD 6 weeks.
Study NCT02236858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA Air Cleaner
Description: Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
Study NCT02236858 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HEPA Air Cleaner
Description: Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
Study NCT01932021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adipose tissue grafting
Study NCT04565587 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Xanthan-gum based thickener
Description: Participants will undergo a screening procedure (V-VST) with two of the viscosities levels determined and prepared with mineral water and Tsururinko Quickly (200 and 800mPa·s). After the V-VST, a Videofluoroscopy (VFS) will be performed with thin liquid and 5 viscosity levels prepared with X-Ray contrast (Omnipaque), mineral water and Tsururinko Quickly (100, 200, 400, 800, 1600mPa·s). Participants swallow will be studied with VFS in a lateral projection and images will include the oral cavity, pharynx, larynx and cervical oesophagus. Swallows will be analysed by equipment developed to capture and digitize the swallowing sequences to assess VFS signs of safety and efficacy according to accepted definitions and to measure the timing and spatial events of the swallow response.
Study NCT01487720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
Study NCT06251349 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: Single dose radiation with 7-8 Gy
Study NCT06251349 — intervention group
Intervention type: DRUG
Intervention: Diclofenac
Description: postoperative treatment with diclofenac to prevent HO
Study NCT04469751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: invasive blood pressure monitoring
Description: radial artery and dorsalis pedis artery intubated with BD Insyte-W 22G artery puncture needle under local anaesthesia
Study NCT01206595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402
Description: Single dose of SKY0402 administered as a nerve block
Study NCT01206595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Single dose of 125 mg administered as a nerve block
Study NCT00447213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patient specific, injected, daily, 24 weeks
Study NCT02873260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraVax-DV-TV005
Description: TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02873260 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rDEN3Δ30
Description: Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02873260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3Δ30
Description: Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
Study NCT02873260 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
Study NCT00447213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals,12 weeks
Study NCT00447213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Insulin
Description: Patient specific dose,injected, before meals, 12 weeks
Study NCT01475292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 50 ug administered via a nebuliser once daily for 14 days
Study NCT01647256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nikkomycin Z
Description: Capsule, 500 mg, single-dose
Study NCT01594372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy with sacropexy
Description: Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
Study NCT01594372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral colposuspension
Description: Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
Study NCT04015141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Oral Suspension
Description: Perampanel oral suspension.
Study NCT04015141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel Tablet
Description: Perampanel tablet.
Study NCT02885168 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared spectroscopy (NIRS)
Description: After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
Study NCT02885168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS)
Description: After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
Study NCT02885168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine
Description: Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test.